CN102065865B - 多发性骨髓瘤治疗 - Google Patents

多发性骨髓瘤治疗 Download PDF

Info

Publication number
CN102065865B
CN102065865B CN2009801229778A CN200980122977A CN102065865B CN 102065865 B CN102065865 B CN 102065865B CN 2009801229778 A CN2009801229778 A CN 2009801229778A CN 200980122977 A CN200980122977 A CN 200980122977A CN 102065865 B CN102065865 B CN 102065865B
Authority
CN
China
Prior art keywords
cells
purposes
treatment
myeloma
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801229778A
Other languages
English (en)
Chinese (zh)
Other versions
CN102065865A (zh
Inventor
恩瑞克·奥西奥
阿塔纳希奥·帕恩迪耶拉
赫苏斯·圣米格尔
帕布鲁·曼努埃尔·阿维莱斯马林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of CN102065865A publication Critical patent/CN102065865A/zh
Application granted granted Critical
Publication of CN102065865B publication Critical patent/CN102065865B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801229778A 2008-05-16 2009-05-18 多发性骨髓瘤治疗 Expired - Fee Related CN102065865B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08380154 2008-05-16
EP08380154.8 2008-05-16
PCT/EP2009/055978 WO2009138509A1 (en) 2008-05-16 2009-05-18 Multiple myeloma treatments

Publications (2)

Publication Number Publication Date
CN102065865A CN102065865A (zh) 2011-05-18
CN102065865B true CN102065865B (zh) 2013-03-20

Family

ID=40848780

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801229778A Expired - Fee Related CN102065865B (zh) 2008-05-16 2009-05-18 多发性骨髓瘤治疗

Country Status (12)

Country Link
US (1) US8435992B2 (enExample)
EP (1) EP2303274A1 (enExample)
JP (1) JP2011520846A (enExample)
KR (1) KR20110028454A (enExample)
CN (1) CN102065865B (enExample)
AU (1) AU2009248039B2 (enExample)
CA (1) CA2724206A1 (enExample)
IL (1) IL209360A (enExample)
MX (1) MX2010012358A (enExample)
NZ (1) NZ589270A (enExample)
RU (1) RU2519750C2 (enExample)
WO (1) WO2009138509A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
EP2307003A2 (en) * 2008-05-16 2011-04-13 Pharma Mar S.A. Combination therapy with pm00104 and another antitumor agent
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
KR101471273B1 (ko) * 2013-01-29 2014-12-11 인제대학교 산학협력단 Ｓｏｄ２를 포함하는 보르테조밉 내성 진단용 바이오 마커 조성물 및 이를 이용한 진단 키트
KR101718800B1 (ko) 2015-01-21 2017-03-24 주식회사 디알나노 약물 및 ｓｉＲＮＡ의 공동―운반용 나노복합체 및 이의 용도
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1211386A (zh) * 1997-09-16 1999-03-24 林禾杰 对虾高产养殖新方法
WO2007052076A2 (en) * 2005-10-31 2007-05-10 Pharma Mar, S.A. Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US6569859B1 (en) 2000-02-22 2003-05-27 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
JP4584245B2 (ja) * 2003-03-12 2010-11-17 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 多発性骨髄腫治療用のアプリジン
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1211386A (zh) * 1997-09-16 1999-03-24 林禾杰 对虾高产养殖新方法
WO2007052076A2 (en) * 2005-10-31 2007-05-10 Pharma Mar, S.A. Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases

Also Published As

Publication number Publication date
AU2009248039B2 (en) 2014-07-31
NZ589270A (en) 2011-12-22
CA2724206A1 (en) 2009-11-19
RU2519750C2 (ru) 2014-06-20
US8435992B2 (en) 2013-05-07
JP2011520846A (ja) 2011-07-21
KR20110028454A (ko) 2011-03-18
RU2010151660A (ru) 2012-06-27
IL209360A0 (en) 2011-01-31
CN102065865A (zh) 2011-05-18
US20110076343A1 (en) 2011-03-31
IL209360A (en) 2015-10-29
AU2009248039A1 (en) 2009-11-19
EP2303274A1 (en) 2011-04-06
WO2009138509A1 (en) 2009-11-19
MX2010012358A (es) 2011-01-25

Similar Documents

Publication Publication Date Title
CN102065865A (zh) 多发性骨髓瘤治疗
US11446309B2 (en) Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
RU2743643C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
AU2012321110B2 (en) Combination treatment
US10583129B2 (en) Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
TWI746449B (zh) 使用阿吡莫德治療癌症之方法
TWI688387B (zh) 二氫槲皮素或其醫藥上可接受之鹽、或含有彼之組合物的醫藥用途
TW202333675A (zh) 用於治療癌症之組合療法之用途
US20240285640A1 (en) Combination therapy for treating pik3ca-mutated cancer
TW202435896A (zh) 包含阿茲夫定和化療試劑的抗腫瘤藥物組合物
CA3030967C (en) Combination of a bcl-2 inhibitor and a mcl-1 uses and pharmaceutical compositions thereof
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
KR20260018053A (ko) Bcl2 억제제에 노출 이력이 없는 대상체의 암 치료 방법
EP3880207A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
US20190365680A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
JP2023537290A (ja) 癌を処置するためのＢｃｌ－２阻害薬と低メチル化剤との組合せ、その使用及び医薬組成物
CN102083436A (zh) 抗肿瘤组合物和方法
HK40092504A (en) Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof
WO2025090844A1 (en) Methods of treating cancer associated with reduced interleukin 1 beta expression
CN103933539B (zh) 一种含有四环素的药物组合物及其应用
TW202315615A (zh) Pi3k抑制劑與btk抑制劑在製備治療淋巴瘤的藥物中的用途
TW202434219A (zh) 使用乏氧激活化合物治療對parp抑制劑耐藥的患者的藥物及其製藥用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Ocio Enrique

Inventor after: Pandiella Atanasio

Inventor after: San Miguel Jesus

Inventor after: Aviles Marin Pablo Manuel

Inventor before: Ocio Enrique

Inventor before: Pandiella Atanasio

Inventor before: San Miguel Jesus

Inventor before: Aviles Marin Pablo Manuel

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130320

Termination date: 20170518